Use of Hydrogen as a Novel Therapeutic Strategy Against Photoreceptor Degeneration in Retinitis Pigmentosa Patients.
Ye Tao, Lei Geng, Liqiang Wang, Weiwei Xu, Limin Qin, Guanghua Peng, Yi Fei Huang, Ji xue Yang · Medical science monitor : international medical journal of experimental and clinical research · 2016
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
Based on these findings, the researchers hypothesize that hydrogen might be an effective therapeutic agent to slow or prevent photoreceptor degeneration in RP retinas. This source-grounded publication contributes evidence relevant to molecular hydrogen and is retained in a transparent general research category when a more specific study design is not supported by the indexed record.
How Molecular Hydrogen Was Addressed
It is a logical step to test hydrogen for therapeutic use in multiple RP animal models, and ultimately in human RP patients.
What the Publication Reported
Hydrogen is so mild that it does not disturb the metabolic oxidation-reduction reactions or disrupt the physiologic ROS involved in cell signaling.
H₂ Mechanisms / Biological Findings
Hydrogen is so mild that it does not disturb the metabolic oxidation-reduction reactions or disrupt the physiologic ROS involved in cell signaling. It has been verified that hydrogen is capable of neutralizing the cytotoxic ROS selectively, rectifying abnormities in the apoptotic cascades, and attenuating the related inflammatory response. Based on these findings, the researchers hypothesize that hydrogen might be an effective therapeutic agent to slow or prevent photoreceptor degeneration in RP retinas.